drug
Bortezomib Pfizer
Marketedupdated 5mo agoby Hospira Inc
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 4Small molecule drug with a maximum clinical stage of Approval (across all indications), with an approval for multiple myeloma and mantle cell lymphoma and 36 investigational indications.
all catalysts(1)
Trials studying Bortezomib Pfizer
- phase3A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Cilta-cel, a CAR-T Therapy Directed Against BCMA Versus VRd Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom ASCT is Not Planned as Initial Therapy
- phase22015-12: A Study Exploring the Use of Early and Late Consolidation/Maintenance Therapy
- phase3A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
- phase3Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma
- phase2A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants With Relapsed-Refractory Multiple Myeloma (RRMM)
- phase3MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
- phase2Daratumumab Based Response Adapted Therapy for Older Adults With Newly Diagnosed Multiple Myeloma
- phase3Elranatamab/Lenalidomide Consolidation and/or Elranatamab Maintenance Versus Standard of Care After D-VRd Induction in Transplant-eligible NDMM Patients
Patent cliff
source: FDA Orange Bookfirst barrier falls
Nov 3, 2032
~6.1 years out
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (7)
- Sep 23, 2042method-of-use (U-3633)US 11679119
- Sep 23, 2042method-of-use (U-3633)US 11679119
- Sep 23, 2042method-of-use (U-3633)US 11752164
- Sep 23, 2042method-of-use (U-3633)US 11752164
- Sep 23, 2042formulationUS 12005069
- Sep 23, 2042formulationUS 12005069
- Nov 3, 2032formulationUS 8962572
News(1)
- Dr Chari on Frontline Combinations and Transplant Approaches in Multiple MyelomaAjai Chari, MD, discusses frontline treatment and transplant considerations in multiple myeloma.onclive · 5mo ago
Data sources
last refreshed 2h ago
Found something off?
comments(0)
5-min edit window · permanent after that